Table 1 Baseline characteristics and treatment details of rectal cancer patients treated with preoperative chemoradiation with capecitabine (n = 746)
Sex | |
 Male | 477 (64%) |
 Female | 269 (35%) |
Age (years) | 64 (57–71) |
T-stage | |
 2 | 33 (5%) |
 3 | 539 (76%) |
 4 | 134 (19%) |
N-stage | |
 0 | 102 (14%) |
 1 | 265 (37%) |
 2 | 346 (49%) |
M-stage | |
 0 | 659 (90%) |
 1 | 74 (10%) |
Primary rectal cancer | 713 (96%) |
Recurrent rectal cancer | 33 (4%) |
BMI (kg/m2) | 25.8 (23.5–28.7) |
Skeletal muscle mass | |
 Normal | 306 (49%) |
 Low | 324 (51%) |
Skeletal muscle density | |
 Normal | 353 (56%) |
 Low | 278 (44%) |
Capecitabine dosing scheme | |
 Weekdays only | 300 (40%) |
 Continuous | 446 (60%) |
Renal function | |
 eGFR < 60 ml/min/1.73 m2 | 51 (7%) |
 eGFR ≥ 60 ml/min/1.73 m2 | 694 (93%) |
Diarrhea | |
 No diarrhea | 543 (73%) |
 Grade 1 | 90 (12%) |
 Grade 2 | 43 (6%) |
 Grade 3 | 68 (9%) |
 Grade 4 | 1 (0%) |
 Grade 5 | 1 (0%) |